Marshall Wace LLP 13D and 13G filings for Esperion Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-16 09:56 am Sale |
2020-12-31 | 13G | Esperion Therapeutics, Inc. ESPR |
Marshall Wace LLP | 1,370,352 4.900% |
-157,749 (-10.32%) |
Filing |
| 2020-06-15 4:44 pm Purchase |
2020-06-03 | 13G | Esperion Therapeutics, Inc. ESPR |
Marshall Wace LLP | 1,528,101 5.500% |
1,528,101 (New Position) |
Filing |